Kala Pharmaceuticals Inc

$0.36 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Kala Pharmaceuticals Inc

Kala Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for diseases of the eye. The Company's product candidate includes EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% and INVELTYS (loteprednol etabonate ophthalmic suspension) 1%. Its EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, is a short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. INVELTYS (loteprednol etabonate ophthalmic suspension) 1%, is a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. The Company's AMPPLIFY technology uses selectively-sized nanoparticles that each have a proprietary coating. Its Preclinical Development Programs include rTKI Program for Retinal Diseases (KPI-285/KPI-286), SEGRM Program and Surface Targeted Steroid Program (KPI-333).

Stock Analysis

last close $0.38
1-mo return -37.2%
3-mo return -75%
avg daily vol. 1.81M
52-week high 6.11
52-week low 0.34
market cap. $29M
forward pe -
annual div. -
roe -278%
ltg forecast -
dividend yield -
annual rev. $9M
inst own. 32.9%
baraka

Subscribe now for daily local and international financial news

Subscribe